Ikarian Capital
Overview
At Ikarian Capital, we leverage our medical background to invest both long and short in biotechnology and pharmaceuticals, industries that focus on improving health and the quality of life. Our disciplined research and risk processes reflect the importance we place on long-term capital preservation. We are committed to building an enduring business with strong values and high ethical standards.
Investment Focus
- Innovative drug discovery and development companies
- Strong business fundamentals
- Early to late-stage clinical trials
Portfolio Companies
Get the full list of 54,000+ investors
Ikarian Capital and every other firm and angel in the database — as one spreadsheet you keep.
$19one-time payment · no subscription- All 54,000+ investors — VC firms, private equity, family offices and angels
- The key person to contact at each one, with their job title
- Their work email address
- Their phone number
- Their LinkedIn profile
- Delivered as a single .xlsx file — download it as many times as you like
Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.
Frequently asked questions about Ikarian Capital
What sectors does Ikarian Capital invest in?
Ikarian Capital invests in Pharmaceuticals and Biotechnology, and is based in Dallas, Texas, United States. Ikarian Capital is listed as a private investment firm in the ConnectSafely investor database.
What stage does Ikarian Capital invest at?
Ikarian Capital backs companies at Early Stage, Growth and Late Stage, writing cheques of 1M - 50M.
Which regions does Ikarian Capital invest in?
Ikarian Capital invests across United States.
What companies has Ikarian Capital invested in?
Ikarian Capital's portfolio includes Solid Biosciences, BioAtla, Renovacor and Forte Biosciences.
How do I contact Ikarian Capital?
Ikarian Capital's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.
Last updated · Source: ConnectSafely investor database
